Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of t... Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. 더 보기
Nuvation Bio Inc. (NYSE: NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder, President, and Chief...
Taletrectinib will be marketed in China by Innovent Biologics Approval is based on the pivotal Phase 2 TRUST-I study, demonstrating taletrectinib's durable responses and prolonged...
New Drug Application (NDA) is based on pooled data from the pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib that demonstrated durable responses and prolonged progression-free...
Innovent Receives Approval of DOVBLERON® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) by China's National Medical Products Administration PR Newswire SAN FRANCISCO and SUZHOU, China, Dec. 20...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder...
Nuvation Bio Inc. (NYSE: NUVB), a late clinical-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced that David Hung, M.D., Founder...
Submitted New Drug Application (NDA) for taletrectinib to the U.S. Food and Drug Administration (FDA) in October for the treatment of patients with advanced ROS1-positive (ROS1+) non-small cell...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.34 | -11.7647058824 | 2.89 | 2.99 | 2.44 | 2981144 | 2.63521671 | CS |
4 | -0.06 | -2.29885057471 | 2.61 | 3.455 | 2.44 | 2928053 | 2.79727153 | CS |
12 | 0.25 | 10.8695652174 | 2.3 | 3.455 | 2.18 | 2528166 | 2.73707239 | CS |
26 | -0.8371 | -24.7143574149 | 3.3871 | 3.97 | 2 | 1942291 | 2.77253868 | CS |
52 | 0.97 | 61.3924050633 | 1.58 | 4.1598 | 1.43 | 1684476 | 2.82717362 | CS |
156 | -3.3 | -56.4102564103 | 5.85 | 6.23 | 0.95 | 1118091 | 2.72002284 | CS |
260 | -7.45 | -74.5 | 10 | 15.23 | 0.95 | 1061011 | 4.20481321 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관